-

Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

China’s private sector

China’s drug and medical device sector fuels growth with record licensing deals

China’s pharmaceutical industry surges on ageing demand and global expansion, with revenue forecast to top US$2.1 trillion by 2030.

Innovative drugs are expected to outpace other segments with an annualised growth of 20 per cent between 2026 and 2030, according to UBS. Photo: Shutterstock
Innovative drugs are expected to outpace other segments with an annualised growth of 20 per cent between 2026 and 2030, according to UBS. Photo: Shutterstock
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Advertisement
Advertisement
Advertisement
Banking & finance

TCM firms eye Hong Kong IPOs to fuel global expansion

Over the past year, 34 innovation and technology, life and health science companies set up or expanded their operations in Hong Kong.

A traditional Chinese medicine pharmacy at the Hong Kong Chinese Medicine Hospital in Tseung Kwan O. Photo: Edmond So
A traditional Chinese medicine pharmacy at the Hong Kong Chinese Medicine Hospital in Tseung Kwan O. Photo: Edmond So
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
IPO

China’s Zhipu AI launches US$560 million share sale amid heated IPO tech race

The company, marketed overseas as Z.ai, eyes US$6.6 billion valuation with Hong Kong’s first large language model listing.

Zhipu AI is moving closer to becoming the first large language model developer listed in Hong Kong. Photo: Shutterstock
Zhipu AI is moving closer to becoming the first large language model developer listed in Hong Kong. Photo: Shutterstock
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

Medicine

Sanofi signs with Hong Kong biotech firm Insilico to spur AI drug discovery

French pharmaceutical giant Sanofi will collaborate with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion to speed up the drug-discovery process using artificial intelligence.

videocam
Advertisement
Advertisement
Advertisement
Medicine

Exclusive | Hong Kong’s Insilico, Aramco to partner on sustainable fuels and materials

AI drug discovery unicorn Insilico Medicine is set to sign a deal with Saudi Arabia’s Aramco and a subsidiary during Hong Kong leader John Lee Ka-chiu’s official visit to the country.

videocam
Insilico opened a regional research centre in Abu Dhabi this month. The opening ceremony was attended by Alex Zhavoronkov, Insilico’s co-founder and CEO, Omar Al Olama, the UAE’s Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Ahmed Baghoum, the acting CEO of Masdar City, and Alex Aliper, Insilico’s co-founder and president. Photo: Handout
Insilico opened a regional research centre in Abu Dhabi this month. The opening ceremony was attended by Alex Zhavoronkov, Insilico’s co-founder and CEO, Omar Al Olama, the UAE’s Minister of State for Artificial Intelligence, Digital Economy and Remote Work Applications, Ahmed Baghoum, the acting CEO of Masdar City, and Alex Aliper, Insilico’s co-founder and president. Photo: Handout
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

Banking & finance

From chips to noodles: the newcomers testing Hong Kong’s buoyant IPO market

A wave of billion-dollar offerings is building behind four new listings this week, signalling sustained momentum in Hong Kong’s IPO market.

Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shenyang-based 3SBio is selling a 4.14 per cent stake in the company. Photo: Handout
Help preserve 120 years of quality journalism.
SUPPORT NOW